Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26668641 | 0.85 | KCNH2 (0.36) | — | |
| SCHEMBL26668640 | 0.78 | — | — | |
| SCHEMBL29632578 | 0.71 | KDM4E (0.36) | MAPTTP53CYP1A2CYP19A1CYP2C9 | |
| SCHEMBL24936302 | 0.71 | KDM4E (0.36) | MAPTTP53CYP1A2CYP19A1CYP2C9 | |
| SCHEMBL25267484 | 0.70 | CYP3A4 (0.53) | MAPTLMNACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL29045194 | 0.69 | CYP1A2 (0.35) | LMNACYP1A2CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL24936185 | 0.67 | KCNH2 (0.52) | CYP2C19 | |
| SCHEMBL7189697 | 0.67 | SLC40A1 (0.37) | MAPT | |
| SCHEMBL371799 | 0.66 | PDGFRB (0.51) | — | |
| SCHEMBL29788605 | 0.65 | MEN1 (0.47) | MAPTTP53LMNACYP1A2CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260022109-A1 | 5-HETEROARYL-1H-PYRAZOL-3-AMINE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2026-01-22 | — | — | US | disclosed |
| US-20250352541-A1 | THERAPEUTIC FOR CANCER REFRACTORY TO IMMUNE CHECKPOINT INHIBITOR | Sumitomo Pharma Co., Ltd. (JP) | 2025-11-20 | — | — | US | disclosed |
| US-12410154-B2 | 5-heteroaryl-1H-pyrazol-3-amine derivative | Sumitomo Pharma Co., Ltd. (JP) | 2025-09-09 | — | — | US | disclosed |
| EP-4534100-A1 | THERAPEUTIC FOR CANCER REFRACTORY TO IMMUNE CHECKPOINT INHIBITOR | Sumitomo Pharma Co., Ltd. (JP) | 2025-04-09 | — | — | EP | disclosed |
| WO-2023229032-A1 | THERAPEUTIC FOR CANCER REFRACTORY TO IMMUNE CHECKPOINT INHIBITOR | 住友ファーマ株式会社 | 2023-11-30 | — | — | WO | disclosed |
| EP-4253377-A1 | 5-HETEROARYL-1H-PYRAZOL-3-AMINE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2023-10-04 | — | — | EP | disclosed |
| CN-116546974-A | 5-heteroaryl-1H-pyrazol-3-amine derivatives | 住友制药株式会社 | 2023-08-04 | — | — | CN | disclosed |
| US-11564920-B2 | 5-heteroaryl-1H-pyrazol-3-amine derivative | Sumitomo Pharma Co., Ltd. (JP) | 2023-01-31 | — | — | US | disclosed |
| US-11564920-B2 | 5-heteroaryl-1H-pyrazol-3-amine derivative | Sumitomo Pharma Co., Ltd. (JP) | 2023-01-31 | — | — | US | disclosed |
| US-20230025065-A1 | 5-HETEROARYL-1H-PYRAZOL-3-AMINE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2023-01-26 | — | — | US | disclosed |
| US-20230025065-A1 | 5-HETEROARYL-1H-PYRAZOL-3-AMINE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2023-01-26 | — | — | US | disclosed |
| US-20220273649-A1 | 5-HETEROARYL-1H-PYRAZOL-3-AMINE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2022-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11564920-B2 | 5-heteroaryl-1H-pyrazol-3-amine derivative | CHEK1, CHEK2, RB1 | MAPT 4546/4885TP53 16/4885LMNA 2236/4885 |
| US-20230025065-A1 | 5-HETEROARYL-1H-PYRAZOL-3-AMINE DERIVATIVE | CHEK1, CHEK2, RB1 | MAPT 4546/4885TP53 16/4885LMNA 2236/4885 |
| US-20260022109-A1 | 5-HETEROARYL-1H-PYRAZOL-3-AMINE DERIVATIVE | CHEK1, CHEK2, WEE1 | MAPT 4164/4885TP53 35/4885LMNA 1378/4885 |
| US-20220273649-A1 | 5-HETEROARYL-1H-PYRAZOL-3-AMINE DERIVATIVE | CHEK1, CHEK2, RB1 | MAPT 4546/4885TP53 16/4885LMNA 2236/4885 |
| US-12410154-B2 | 5-heteroaryl-1H-pyrazol-3-amine derivative | CHEK1, CHEK2, RB1 | MAPT 4546/4885TP53 16/4885LMNA 2236/4885 |
| US-20250352541-A1 | THERAPEUTIC FOR CANCER REFRACTORY TO IMMUNE CHECKPOINT INHIBITOR | CHEK1, CHEK2, PDCD1 | MAPT 3481/4885TP53 17/4885LMNA 3273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.